Treatment of post menopausal osteoporosis with intravenous pamidronate in patients with esophagogastric pathology;Tratamiento de la osteoporosis postmenopausica con pamidronato intravenoso en pacientes con patologia esofagogastrica

Medicina

Volumn 58, Issue 5 I, 1998, Pages 446-452

  Sarli, Marcelo ^a   Fradinger, Erich ^a   Morillo, Silvia ^a   Rey, Paula ^a   Zanchetta, Jose ^a  

^a Instituto de Investigaciones Metabolicas   (Argentina)

Author keywords

Bisphosphonates; Intravenous pamidronate; Postmenopausal osteoporosis

Indexed keywords

PAMIDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE;

ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERANCE; DRUG USE; ESOPHAGUS DISEASE; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUMBAR SPINE; POSTMENOPAUSE OSTEOPOROSIS; STOMACH DISEASE; TREATMENT INDICATION; AGED; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; DIPHOSPHONATES; ESOPHAGEAL DISEASES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROSPECTIVE STUDIES; STOMACH DISEASES; TREATMENT OUTCOME;

EID: 0031796535     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Zanchetta J, Spivacow F, Bogado C, Sarli M, Plotkin H, Roldán E. Uso prolongado, hasta 6 años, de un aminobisfosfonato oral en pacientes con osteoporosis establecida. Medicina (Buenos Aires) 1997; 57 (Supl 1): 37-44.
2. Spivacow F, Zanchetta J, Kerzberg E, Frigeri A, Fiasché R, Roldán E. Tolerability of oral Pamidronate in elderly patients with osteoporosis and other metabolic bone diseases. Curr Therap Res 1996; 57: 123-30.
3. Fromm G, Vega E, Galich A. Side effects verified during treatment of 228 cases of involutional osteoporosis with Pamidronate. Bone Miner 1992; (Suppl): S17. (Abstract).
4. Degroen P, Lubbe D, Hirsch L, Daifotis A, Stephenson W, Freedhoim D, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 355: 1016-21.
5. Mcclung M. Current bone density data on bisphosphonates in postmenopasual osteoporosis. Bone 1996; 19: s195-S198.
6. Fenton A, Gutteridge D, Neil Kent G, Prince R, Ratallack Roberti Bhagat Ch, Worth G, et al. Intravenous Aminobisphosphonate in Paget's disease: Clinical, biochemical, histomorphometric and radiological responses. Endocrinology 1991; 34: 197-204.
7. Conte P, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate. Results from a multinational randomized controlled trial. J Clin Oncol 1996; 14: 2552-9.
8. Body J, Dumon M, Piccart M, Ford J. Intravenous Pamidronate in patients with tumor-induced osteolysis: A biochemical dose response study. J Bone Miner Res 1995; 10: 1191-6.
9. Liens D, Delmas P, Meunier P. Long-term effects of intravenous pamidronate in fibrous displasia of bone. Lancet 1994; 343: 953-4.
10. World Health Organization assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series. Geneva: 1994.
11. th. World conference on clinical pharmacology and therapeutic (IUPHAR) Buenos Aires.
12. Gallagher S, Fenner J, Anderson K, Bryden F, Bahan S, Logue F, et al. Intravenous Pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung diseases. An open pilot study. Thorax 1992; 47: 932-6.
13. Boutsen Y, Jamart J, Esselink X, Stoffel M, Devogelaer J. Primary prevention of glucocorticoid-induced osteoporosis with intermitent inytavenous Pamidronate: A randomized trial. Calcif Tissue Int. 1997; 61: 266-71.
14. Heikkinen J, Selander K, Laintinen K, Arnala I, Vaananen H. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss. J Bone Miner Res 1997; 12: 103-10.
15. Devogelaer J, Boutsen Y, Nagant de Deuxchaines C. A randommized controlled trial of APD (Disodium Pamidronate) given intravenously with and without sodium fluoride in involutional osteoporosis. In: Osteoporosis 3, Claus Christiansen, C Kristen (eds), Dinamarca 1990; p 1504-5.
16. Passeri M, Baroni M, Pedrazzoni M, Pioli G, Barbagallo M, Costi D, et al. intermittent treatment with intravenous 4-amino-1-hydroxybutilidene-1, 1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone and Mineral 1991; 15: 237-48.
17. Filipponi P, Cristalfini S, Rizzello E, Pollcani G, Fedeli L, Gregorio F, et al. Cyclical intravenous clodronate in postmenopausal osteoporosis: Results of the long-term clinical trial. Bone 196, 18: 179-84.
18. Thiébaud D, Burrckhardt P, Melchior J, Eckert P, Jacquet A, Schnyder P, et al Two years effectiveness of intravenous Pamidronate (APD) versus oral Fluoride for the osteoporosis occurring in the postmenopause. Osteoporosis Int 1994; 4: 76-83.
19. Peretz A, Body J, Dumon J, Rozenberg S, Hotimski A, Praet J, et al. Ciclical Pamidronate infusions in postmenopausal osteoporosis. Maturitas 1996; 25: 69-75.
20. Marcial Toro J, Bartoli D, Vázquez A, Argüelles A, Poggi L. Tratamiento de la osteoporosis postmenopáusica con Pamidronato intravenoso. RAEM. 1995; 32: s50.
21. Lin J. Bisphosphonates. A review of their pharmacokinetic properties. Bone 1996; 18: 75-85.
22. Roldán E, Quattrocchi O, Araujo G, Piccini E. Aplicación clínica de los principios farmacocinéticos de los bisfosfonatos. Medicina (Buenos Aires) 1997; 57 (Supl 1): 76-82.
23. King L, Grynpas M, Tomlinson G, Vieth R. Pamidronate content and turnover in sternum, vertebral body and iliac bones of dogs. Bone 1997; 20: 405-11.
24. Netelembos J, Van Ginkel F, Lips P, Baro R, Van der Weil H, Hackeng W. Effects of a single infusion of Aminohydroxypropilidene on calcium metabolism in healthy volunteers monitored 2 months. J Clin Endocrinol Metab 1991; 72: 223-8.
25. Dumon J, Peretz A, Rozemberg J, Body J. Biochemical effects of a single Pamidronate infusion in postmenopausal osteoporosis. Bone Miner Res 1994; 25 (Supl 1): s 72.
26. Adami S, Zammberlan N, Mian M, Dorizzi R, Rossini M, Braga B, et al. Duration of the effects of intravenous Alendronate in postmenopausal women and in patients with primary hiperparathyroidism and Paget's disease of bone. Bone Miner 1994; 25: 75-82.
27. Valkema R, Vismas F, Papapoulos S, Pauwels E, Bijvoet O. Mantained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 1989; 5: 183-92.
28. Fromm G, Vega E, Plantalech L, Galich A, Mautalen C. Differential action of Pamidronate on trabecular and cortical bone in women with involutional osteoporosis. Osteoporosis Int 1991; 1: 129-33.
29. Liberman U, Weiss S, Broll J, Minne H, Quan H, Bell N, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-43.
30. Tucci J, Tonino R, Emkey R, Peverly C, Kehr C, Santora A. Effect of three yearsof oral Alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996; 101: 488-501.
31. Devogelaer J, Broll H, Correarotter R, Cumming D, Deuxchaines C, Geusens P, et al. Oral Alendronate induces progressive increases in bone mass of the spine, hip, and total body over three years in postmenopausal women with osteoporosis. Bone 1996; 18: 141-50.
32. Massari F, Zanchetta J. I PTH levels in postmenopausal women with osteoporosis treated with alendronate. J Bone Miner Res 1997; 12 (suppl 1): s470.
33. Lufkin E, Aergueta R, Whitaker M, Cameron A, Wong V, Egon K, et al. Pamidronate: An unrecognized problem in gastrointestinal tolerability. Osteoporosis Int 1994; 4: 320-2.
34. O'Donnell N, Rao G, Arguis-Femández A. Paget's disease. Ocular complications of disodium pamidronate treatment. Br J Clin Prac 1995; 49: 272-3.
35. Reid I, Mills D, Wattie D. Ototoxicity associated with intravenous bisphosphonate administration. Calcified Tissue Int 1995; 56: 584-5.